<DOC>
	<DOCNO>NCT02152631</DOCNO>
	<brief_summary>The main purpose study evaluate safe effective study drug know abemaciclib participant lung cancer .</brief_summary>
	<brief_title>A Study Abemaciclib ( LY2835219 ) Participants With Previously Treated KRAS Mutated Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Have confirm diagnosis stage IV nonsmall cell lung cancer ( NSCLC ) accord American Joint Committee Cancer Staging Handbook . Determined detectable mutation codon 12 13 kirsten rat sarcoma ( KRAS ) oncogene investigational assay study JPBK central laboratory . A KRAS positive mutation result codon 12 13 KRAS oncogene tumor tissue per local laboratory permit 10 % randomized participant . Have progress platinumbased chemotherapy ( without maintenance therapy ) AND receive one additional therapy may include immune checkpoint inhibitor anticancer therapy advance and/or metastatic disease OR judge physician ineligible standard secondline chemotherapy . Participants progress platinumbased chemotherapy immune checkpoint inhibitor ( immunotherapy ) e.g . pembrolizumab nivolumab alone combination agent eligible . Have measureable disease define Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) . Have performance status ( PS ) 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale . Have discontinue previous therapy cancer ( include chemotherapy , radiotherapy , immunotherapy , investigational therapy ) least 21 day myelosuppressive agent 14 day nonmyelosuppressive agent prior receive study drug . Have receive treatment drug receive regulatory approval indication within 14 21 day initial dose study drug nonmyelosuppressive myelosuppressive agent , respectively . Have personal history follow condition : presyncope syncope either unexplained cardiovascular etiology , ventricular arrhythmia ( include limit ventricular tachycardia ventricular fibrillation ) , sudden cardiac arrest . Have presence unstable central nervous system ( CNS ) metastasis . History CNS metastasis stable CNS metastasis allow ( longer require active therapy steroid medication ) . Participants history CNS metastases must brain scan ( example , magnetic resonance image [ MRI ] ) within 28 day randomization document stability , even change symptom .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Therapy , Platinum , Kras +</keyword>
</DOC>